WO2001034197A3 - Oncolytic combinations for the treatment of cancer - Google Patents

Oncolytic combinations for the treatment of cancer Download PDF

Info

Publication number
WO2001034197A3
WO2001034197A3 PCT/US2000/030839 US0030839W WO0134197A3 WO 2001034197 A3 WO2001034197 A3 WO 2001034197A3 US 0030839 W US0030839 W US 0030839W WO 0134197 A3 WO0134197 A3 WO 0134197A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
oncolytic
combinations
oncolytic combinations
Prior art date
Application number
PCT/US2000/030839
Other languages
French (fr)
Other versions
WO2001034197A2 (en
Inventor
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Original Assignee
Lilly Co Eli
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jason Scott Sawyer, Beverly Ann Teicher, Douglas Wade Beight, Edward C R Smith, William Thomas Mcmillen filed Critical Lilly Co Eli
Priority to AU19165/01A priority Critical patent/AU1916501A/en
Publication of WO2001034197A2 publication Critical patent/WO2001034197A2/en
Publication of WO2001034197A3 publication Critical patent/WO2001034197A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating cancer with radiation, in conjunction with the administration of a leukotriene (LTB4) antagonist is disclosed.
PCT/US2000/030839 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer WO2001034197A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19165/01A AU1916501A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16470499P 1999-11-11 1999-11-11
US60/164,704 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034197A2 WO2001034197A2 (en) 2001-05-17
WO2001034197A3 true WO2001034197A3 (en) 2002-05-10

Family

ID=22595710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030839 WO2001034197A2 (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer

Country Status (2)

Country Link
AU (1) AU1916501A (en)
WO (1) WO2001034197A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
EP1326605A4 (en) * 2000-05-09 2004-03-17 Univ Creighton Methods for inhibiting proliferation and inducing apoptosis in cancer cells
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
CN110803987B (en) * 2019-11-07 2022-10-14 苏州开元民生科技股份有限公司 Preparation method of R- (+) -2- (4-hydroxyphenoxy) propionic acid

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544488A2 (en) * 1991-11-25 1993-06-02 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544488A2 (en) * 1991-11-25 1993-06-02 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
WO1996006604A2 (en) * 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
WO2001034137A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034135A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer

Also Published As

Publication number Publication date
AU1916501A (en) 2001-06-06
WO2001034197A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
AU2001294604A1 (en) Improved radiation therapy treatment method
AU4564200A (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU2001282717A1 (en) Cancer treatment by combination therapy
AU7380500A (en) Methods for treating tumors using neutron therapy
ZA200200607B (en) On premise water treatment system and method.
MXPA02005735A (en) Enzyme treatment for infection.
WO2001034137A3 (en) Oncolytic combinations for the treatment of cancer
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
AU3724100A (en) An efficient method for subsurface treatments, including squeeze treatments
WO2001034197A3 (en) Oncolytic combinations for the treatment of cancer
AU1280100A (en) Novel 2-pyridone derivatives, preparation method and therapeutic use
ZA200003706B (en) Cyclobutene derivatives, their preparation and their therapeutic uses.
AU2627800A (en) Treatment of lymphomas, leukemias, and leiomyomas
ZA200001746B (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use.
WO2001034199A3 (en) Oncolytic combinations for the treatment of cancer
WO2001034135A3 (en) Oncolytic combinations for the treatment of cancer
AU3913900A (en) Radioenhanced cancer treatment using orally administered camptothecin derivatives
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
ZA200107736B (en) Improved cancer treatment with temozolomide.
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
WO2001034133A3 (en) Oncolytic combinations for the treatment of cancer
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU1201801A (en) Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase